QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-SEC Filing

Core News & Articles

Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Condition...

Core News & Articles

Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $43 to $75.

Core News & Articles

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congres...

Core News & Articles

GRAIL (NASDAQ:GRAL) reported quarterly losses of $(3.18) per share which beat the analyst consensus estimate of $(3.90) by 18.3...

 wall-street-rises-ahead-of-fed-payment-stocks-fall-on-stablecoin-bill-whats-driving-markets-wednesday

U.S. stocks inched higher by midday Wednesday, as traders weighed geopolitical uncertainty and awaited the Federal Reserve'...

Core News & Articles

Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $32 to $43.

Core News & Articles

GRAIL (NASDAQ:GRAL) reported quarterly losses of $(3.10) per share which beat the analyst consensus estimate of $(4.11) by 24.5...

Core News & Articles

Real-World Data in 100,000 Patients Further Support the Galleri® Test's Ability to Simultaneously Screen for Multiple Cance...

 quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence

Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for sales...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION